Market Cap | 110.28B | P/E | 78.66 | EPS this Y | 16.50% | Ern Qtrly Grth | 25.20% |
Income | 2.09B | Forward P/E | 48.21 | EPS next Y | 15.30% | 50D Avg Chg | -4.00% |
Sales | 7.57B | PEG | 5.18 | EPS past 5Y | 12.37% | 200D Avg Chg | 14.00% |
Dividend | N/A | Price/Book | 9.28 | EPS next 5Y | 14.08% | 52W High Chg | -12.00% |
Recommedations | 2.00 | Quick Ratio | 4.03 | Shares Outstanding | 355.35M | 52W Low Chg | 74.00% |
Insider Own | 0.52% | ROA | 7.99% | Shares Float | 353.23M | Beta | 1.40 |
Inst Own | 90.59% | ROE | 15.77% | Shares Shorted/Prior | 3.97M/3.74M | Price | 313.87 |
Gross Margin | 66.86% | Profit Margin | 27.65% | Avg. Volume | 1,687,895 | Target Price | 493.23 |
Oper. Margin | 28.23% | Earnings Date | Oct 17 | Volume | 1,886,343 | Change | -3.11% |
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Evercore ISI Group | In-Line | Oct 1, 24 |
BTIG | Buy | Aug 28, 24 |
Citigroup | Buy | Aug 22, 24 |
Redburn Atlantic | Buy | Aug 2, 24 |
Barclays | Overweight | Jul 23, 24 |
JP Morgan | Overweight | Jul 19, 24 |
Morgan Stanley | Equal-Weight | Jul 19, 24 |
Truist Securities | Buy | Jul 19, 24 |
BTIG | Buy | Jul 19, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Curet Myriam | EVP & Chief Medical.. EVP & Chief Medical Officer | Jan 26 | Sell | 370.15 | 4,318 | 1,598,308 | 189 | 01/29/24 |
Curet Myriam | EVP & Chief Medical.. EVP & Chief Medical Officer | Jan 26 | Option | 180.41 | 4,318 | 779,010 | 1,689 | 01/29/24 |
LEVY ALAN J | Director Director | Jan 26 | Sell | 370.2 | 2,000 | 740,400 | 25,319 | 01/29/24 |
LEVY ALAN J | Director Director | Jan 26 | Option | 122.37 | 2,000 | 244,740 | 27,247 | 01/29/24 |
Johnson Amal M | Director Director | Jan 26 | Sell | 370.08 | 6,696 | 2,478,056 | 11,706 | 01/29/24 |
Johnson Amal M | Director Director | Jan 26 | Option | 56.97 | 6,696 | 381,471 | 18,402 | 01/29/24 |
DeSantis Robert | EVP & Chief Strategy.. EVP & Chief Strategy & Corp Op | Nov 14 | Sell | 290 | 867 | 251,430 | 7,259 | 11/15/23 |
DeSantis Robert | EVP & Chief Strategy.. EVP & Chief Strategy & Corp Op | Nov 14 | Option | 243.97 | 867 | 211,522 | 7,529 | 11/15/23 |
LEVY ALAN J | Director Director | Nov 14 | Sell | 290 | 2,000 | 580,000 | 25,319 | 11/15/23 |
LEVY ALAN J | Director Director | Nov 14 | Option | 90.49 | 2,000 | 180,980 | 27,319 | 11/15/23 |
GUTHART GARY S | CEO CEO | Oct 24 | Sell | 267.99 | 32,345 | 8,668,137 | 29,840 | 10/26/23 |
GUTHART GARY S | CEO CEO | Oct 24 | Option | 49.34 | 33,750 | 1,665,225 | 50,936 | 10/26/23 |
DeSantis Robert | EVP & Chief Strategy.. EVP & Chief Strategy & Corp Op | Oct 24 | Sell | 272.95 | 1,110 | 302,974 | 7,259 | 10/25/23 |
DeSantis Robert | EVP & Chief Strategy.. EVP & Chief Strategy & Corp Op | Oct 24 | Option | 188.86 | 1,110 | 209,635 | 7,823 | 10/25/23 |
Ladd Amy L | Director Director | Sep 14 | Sell | 305.68 | 500 | 152,840 | 702 | 09/15/23 |
LEVY ALAN J | Director Director | Aug 07 | Sell | 310 | 2,000 | 620,000 | 25,319 | 08/08/23 |
LEVY ALAN J | Director Director | Aug 07 | Option | 80.91 | 2,000 | 161,820 | 25,784 | 08/08/23 |
DeSantis Robert | EVP & Chief Strategy.. EVP & Chief Strategy & Corp Op | Jul 25 | Sell | 323.13 | 2,535 | 819,135 | 7,259 | 07/26/23 |
DeSantis Robert | EVP & Chief Strategy.. EVP & Chief Strategy & Corp Op | Jul 25 | Option | 224.14 | 2,535 | 568,195 | 7,823 | 07/26/23 |
MOHR MARSHALL | Executive VP Global.. Executive VP Global Business S | Jun 14 | Sell | 325 | 11,250 | 3,656,250 | 24,136 | 06/15/23 |
MOHR MARSHALL | Executive VP Global.. Executive VP Global Business S | Jun 14 | Option | 59.46 | 11,250 | 668,925 | 35,386 | 06/15/23 |
BARRATT CRAIG H | Director Director | Jun 14 | Sell | 322.78 | 1,567 | 505,796 | 06/15/23 | |
BARRATT CRAIG H | Director Director | Jun 14 | Option | 41.26 | 1,567 | 64,654 | 1,567 | 06/15/23 |
DeSantis Robert | EVP & Chief Product.. EVP & Chief Product Officer | Jun 14 | Sell | 325 | 2,443 | 793,975 | 7,259 | 06/15/23 |
DeSantis Robert | EVP & Chief Product.. EVP & Chief Product Officer | Jun 14 | Option | 290.33 | 2,443 | 709,276 | 9,702 | 06/15/23 |
BARRATT CRAIG H | Director Director | May 01 | Sell | 306 | 2,000 | 612,000 | 05/02/23 | |
BARRATT CRAIG H | Director Director | May 01 | Option | 41.26 | 2,000 | 82,520 | 2,000 | 05/02/23 |
RUBASH MARK J | Director Director | Apr 28 | Sell | 300 | 7,323 | 2,196,900 | 15,482 | 05/01/23 |
RUBASH MARK J | Director Director | Apr 28 | Option | 169.93 | 7,323 | 1,244,397 | 16,005 | 05/01/23 |
RUBASH MARK J | Director Director | Apr 27 | Option | 0.0 | 482 | 15,482 | 04/28/23 | |
Reed Monica P | Director Director | Apr 27 | Option | 0.0 | 482 | 1,037 | 04/28/23 | |
NACHTSHEIM JAMI K | Director Director | Apr 27 | Option | 0.0 | 482 | 5,063 | 04/28/23 | |
Ladd Amy L | Director Director | Apr 27 | Option | 0.0 | 482 | 1,202 | 04/28/23 | |
LEVY ALAN J | Director Director | Apr 27 | Option | 0.0 | 482 | 25,319 | 04/28/23 | |
Leonard Keith R | Director Director | Apr 27 | Option | 0.0 | 482 | 3,584 | 04/28/23 | |
Beery Joseph C | Director Director | Apr 27 | Option | 0.0 | 482 | 1,802 | 04/28/23 | |
BARRATT CRAIG H | Director Director | Apr 27 | Option | 0.0 | 655 | 25,351 | 04/28/23 | |
KANIA DON R | Director Director | Apr 27 | Option | 0.0 | 482 | 3,269 | 04/28/23 | |
Johnson Amal M | Director Director | Apr 27 | Option | 0.0 | 482 | 11,706 | 04/28/23 | |
Rosa David J. | EVP Chief Strategy &.. EVP Chief Strategy & Growth Of | Apr 21 | Sell | 298.56 | 81,564 | 24,351,748 | 155,712 | 04/24/23 |
Rosa David J. | EVP Chief Strategy &.. EVP Chief Strategy & Growth Of | Apr 21 | Option | 42.64 | 108,000 | 4,605,120 | 196,476 | 04/24/23 |
RUBASH MARK J | Director Director | Apr 21 | Option | 150.87 | 8,135 | 1,227,327 | 15,927 | 04/24/23 |
RUBASH MARK J | Director Director | Apr 21 | Sell | 297.93 | 8,135 | 2,423,661 | 15,000 | 04/24/23 |
Widman Fredrik | VP Corporate Control.. VP Corporate Controller | Apr 21 | Sell | 297.87 | 630 | 187,658 | 2,233 | 04/24/23 |
DeSantis Robert | EVP & Chief Product.. EVP & Chief Product Officer | Apr 21 | Sell | 297.94 | 8,623 | 2,569,137 | 7,065 | 04/24/23 |
DeSantis Robert | EVP & Chief Product.. EVP & Chief Product Officer | Apr 21 | Option | 210.9 | 6,260 | 1,320,234 | 11,872 | 04/24/23 |
BARRATT CRAIG H | Director Director | Apr 21 | Sell | 297.92 | 6,000 | 1,787,520 | 04/24/23 | |
BARRATT CRAIG H | Director Director | Apr 21 | Option | 41.26 | 6,000 | 247,560 | 2,000 | 04/24/23 |
Curet Myriam | EVP & Chief Medical.. EVP & Chief Medical Officer | Apr 21 | Sell | 299.48 | 9,623 | 2,881,896 | 327 | 04/24/23 |
Curet Myriam | EVP & Chief Medical.. EVP & Chief Medical Officer | Apr 21 | Option | 170.44 | 8,000 | 1,363,520 | 7,950 | 04/24/23 |